In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression

The COVID‐19 pandemic caused by SARS‐CoV‐2 has is a global health challenge. Angiotensin‐converting enzyme 2 (ACE2) is the host receptor for SARS‐CoV‐2 entry. Recent studies have suggested that patients with hypertension and diabetes treated with ACE inhibitors (ACEIs) or angiotensin receptor blocke...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Sanju, Cheng, Kuoyuan, Schäffer, Alejandro A, Aldape, Kenneth, Schiff, Eyal, Ruppin, Eytan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390914/
https://www.ncbi.nlm.nih.gov/pubmed/32729248
http://dx.doi.org/10.15252/msb.20209628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390914/
https://www.ncbi.nlm.nih.gov/pubmed/32729248
http://dx.doi.org/10.15252/msb.20209628

Ejemplares similares